A recent pilot study has indicated that liraglutide, a weight-loss drug classified as a GLP-1 receptor agonist, has the potential to reduce migraine episodes by nearly half among obese individuals suffering from chronic migraines. Presented at an European neurology congress, the study's findings suggest new avenues for treatment, although a lack of a control group means caution is warranted regarding the results. Experts call for more rigorous testing through randomized controlled trials to confirm efficacy and explore the drug's benefits against migraines, a condition affecting millions worldwide.
In a small study, the drug liraglutide reduced monthly migraine episodes by nearly half among people with obesity who experience the headache-inducing condition.
This pilot study's results were presented on 21 June and showed promise for using GLP-1 receptor agonists to treat migraines, though more research is needed.
Lanfranco Pellesi emphasized that the promising results warrant a randomized controlled trial to establish a definitive link between GLP-1 drugs and migraine relief.
Participants had previously attempted at least two other migraine-preventive medications without success, highlighting the potential significance of liraglutide as a new treatment option.
Collection
[
|
...
]